Rosso R - Search Results

1

[Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].

Campora E, Simoni C, Rosso R. Campora E, et al. Among authors: rosso r. Minerva Med. 1994 Jan-Feb;85(1-2):25-31. Minerva Med. 1994. PMID: 8152575 Clinical Trial. Italian.

2

Impact of administration-related factors on outcome of adjuvant chemotherapy for primary breast cancer.

Pronzato P, Campora E, Amoroso D, Bertelli G, Botto F, Conte PF, Sertoli MR, Rosso R. Pronzato P, et al. Among authors: rosso r. Am J Clin Oncol. 1989 Dec;12(6):481-5. doi: 10.1097/00000421-198912000-00004. Am J Clin Oncol. 1989. PMID: 2589228

3

Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment.

Chiara S, Campora E, Simoni C, Confalonieri M, Psilogenis M, Rosso R. Chiara S, et al. Among authors: rosso r. Anticancer Res. 1995 Jul-Aug;15(4):1597-9. Anticancer Res. 1995. PMID: 7654054 Clinical Trial.

4

Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.

Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Campora E, et al. Among authors: rosso r. Am J Clin Oncol. 1994 Dec;17(6):522-6. Am J Clin Oncol. 1994. PMID: 7977174 Clinical Trial.

5

Mitoxantrone in elderly women with advanced breast cancer: a phase II study.

Repetto L, Simoni C, Venturino A, Biancardi V, Gasco M, Campora E, Rosso R. Repetto L, et al. Among authors: rosso r. Anticancer Res. 1995 Sep-Oct;15(5B):2297-300. Anticancer Res. 1995. PMID: 8572641 Clinical Trial.

6

Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.

Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C. Rosso R, et al. Anticancer Res. 1991 Mar-Apr;11(2):937-9. Anticancer Res. 1991. PMID: 1829602 Clinical Trial.

7

Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).

Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R. Campora E, et al. Among authors: rosso r. Oncology. 1991;48(5):403-5. doi: 10.1159/000226969. Oncology. 1991. PMID: 1836058

8

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.

Campora E, Oliva C, Mammoliti S, Cetto GL, Fosser V, Marangolo M, Rosso R. Campora E, et al. Among authors: rosso r. Breast Cancer Res Treat. 1991 Oct;19(2):129-32. doi: 10.1007/BF01980943. Breast Cancer Res Treat. 1991. PMID: 1836746 Clinical Trial.

9

Double-blind randomized trial of lorazepam versus placebo with methylprednisolone for control of emesis due to non-cisplatin containing chemotherapy.

Campora E, Baldini E, Rubagotti A, Chiara S, Bruzzi P, Sertoli MR, Rosso R. Campora E, et al. Among authors: rosso r. J Chemother. 1990 Oct;2(5):336-9. doi: 10.1080/1120009x.1990.11739039. J Chemother. 1990. PMID: 2090773 Clinical Trial.

10

The impact of chemotherapy on the quality of life of breast cancer patients.

Campora E, Naso C, Vitullo MT, Giudici S, Camoirano A, Repetto L, Rosso R. Campora E, et al. Among authors: rosso r. J Chemother. 1992 Feb;4(1):59-63. doi: 10.1080/1120009x.1992.11739141. J Chemother. 1992. PMID: 1383437

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

866 results

Search Page

Filters